Interpreting Primary End Points in Randomized Trials of Pancreatic Cancer

Affiliations

¹ Christoph Springfeld, MD, PhD, Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; Markus W. Büchler, MD, FACS (hon), FRCS (hon), FASA(hon), Botton-Champalimaud Pancreatic Cancer Center, Champalimaud Foundation, Lisbon, Portugal; and John P. Neoptolemos, MA, MB, BChir, MD, FRCS, Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Baden-Württemberg, Germany.

Comment

Christoph Springfeld et al. J Clin Oncol. 2023.

. 2023 Sep 1;41(25):4182-4183.

doi: 10.1200/JCO.23.00779. Epub 2023 Jun 27.

¹ Christoph Springfeld, MD, PhD, Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany; Markus W. Büchler, MD, FACS (hon), FRCS (hon), FASA(hon), Botton-Champalimaud Pancreatic Cancer Center, Champalimaud Foundation, Lisbon, Portugal; and John P. Neoptolemos, MA, MB, BChir, MD, FRCS, Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Baden-Württemberg, Germany.

No abstract available

Comment in

Reply to C. Springfeld et al.
Manji GA. Manji GA. J Clin Oncol. 2023 Sep 1;41(25):4183-4184. doi: 10.1200/JCO.23.01011. Epub 2023 Jun 27. J Clin Oncol. 2023. PMID: 37369091 No abstract available.

Adjuvant Gemcitabine and Nab-Paclitaxel Misses the Target in Pancreas Adenocarcinoma: Or Did an Effective Therapy Fall to the Definition of Recurrence?
Manji GA. Manji GA. J Clin Oncol. 2023 Apr 10;41(11):1972-1975. doi: 10.1200/JCO.23.00039. Epub 2023 Feb 28. J Clin Oncol. 2023. PMID: 36854094 No abstract available.